Ch'ien L T, Whitley R J, Nahmias A J, Lewin E B, Linnemann C C, Frenkel L D, Bellanti J A, Buchanan R A, Alford D A
Pediatrics. 1975 May;55(5):678-85.
Among 13 neonates with herpes simplex virus (HSV) infection, eight had disseminated disease, one localized CNS disease, and in four the infection was confined to the skin and eyes. Ara-A, a purine nucleoside with anti-viral activity against DNA-VIRUSES, WAS GIVEN (10 TO 20 MG/MG/DAY) BY A CONTINUOUS 12-HOUR INTRAVENOUS DRIP FOR 10 TO 15 DAYS. In all, ara-A administration was begun within three to eight days after the appearance of skin vesicles which represented the hallmark of the disease. Both diagnosis and ara-A treatment were much delayed in one infant without skin vesicles and four infants whose skin vesicles appeared late, long after the occurrence of CNS damage. In this group of infants with disseminated disease, four died and one infant was left with severe neurological deficits. Eight infants (four with disseminated and four with localized skin disease) with skin vesicles as the earliest sign of infection received ara-A early, within three days after the onset of neurologic signs. All survived with no neurologic deficit at 6 months to 1 year of age. There was no apparent toxicity of ara-A to the bonemarrow, liver, or kidney.
在13例单纯疱疹病毒（HSV）感染的新生儿中，8例有播散性疾病，1例有局限性中枢神经系统疾病，4例感染局限于皮肤和眼部。阿糖腺苷是一种对DNA病毒有抗病毒活性的嘌呤核苷，通过12小时持续静脉滴注给予（10至20毫克/千克/天），持续10至15天。总体而言，在出现代表该疾病特征的皮肤水疱后的三至八天内开始给予阿糖腺苷治疗。在1例没有皮肤水疱以及4例皮肤水疱出现较晚（在中枢神经系统损伤发生很久之后）的婴儿中，诊断和阿糖腺苷治疗都延迟了很久。在这组有播散性疾病的婴儿中，4例死亡，1例婴儿留有严重的神经功能缺陷。8例以皮肤水疱作为感染最早迹象的婴儿（4例有播散性疾病，4例有局限性皮肤疾病）在神经症状出现后的三天内尽早接受了阿糖腺苷治疗。所有患儿在6个月至1岁时均存活且无神经功能缺陷。阿糖腺苷对骨髓、肝脏或肾脏没有明显毒性。
